A patient with apolipoprotein E2 variant (Q187E) without lipoprotein glomerulopathy

Am J Kidney Dis. 2002 Mar;39(3):E15. doi: 10.1053/ajkd.2002.31426.

Abstract

Four apolipoprotein (apo) E variants have been reported to be associated with lipoprotein glomerulopathy (LPG), which is characterized by type III hyperlipoproteinemia (type III HLP) and proteinuria and frequently leads to nephrotic syndrome. We report the histologic findings in the kidneys of a type III HLP patient with an apo E variant, apo E Toranomon, in which the glutamine at residue 187 in apo E is substituted by glutamic acid (Q187E). The patient also had type 2 diabetes mellitus. No evidence of lipoprotein thrombi suggestive of LPG was detected, however, and the histologic diagnosis was diabetic nephrosclerosis. This unique case illustrates that not all apo E variants result in LPG, and the location of mutations in the apo E protein is one of the important determinants for the development of LPG.

Publication types

  • Case Reports

MeSH terms

  • Apolipoproteins E / genetics*
  • Diabetes Complications
  • Diabetic Nephropathies / diagnosis
  • Diabetic Nephropathies / genetics*
  • Female
  • Humans
  • Middle Aged
  • Nephrosclerosis / diagnosis
  • Nephrosclerosis / genetics*
  • Point Mutation

Substances

  • Apolipoproteins E